Who Qualifies for Semaglutide Weight Loss?

Last reviewed: June 4, 2026

Last updated: June 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide has become a transformative tool for weight management, with clinical trials showing an average 15% body weight reduction over 68 weeks. However, not everyone is a candidate for this GLP-1 therapy, and understanding eligibility criteria helps patients and providers make informed decisions about personalized treatment.

BMI Thresholds and Weight Loss Qualification Standards

Most clinical protocols consider semaglutide therapy for patients with a BMI of 30 kg/m² or higher, or BMI 27 kg/m² with weight-related health complications like hypertension or type 2 diabetes. BMI alone does not determine candidacy—metabolic factors, medication history, and personal health goals matter equally. PlexusDx evaluates the complete clinical picture to match patients with appropriate dosing strategies and compound selection.

Weight-related conditions that may support eligibility include prediabetes, sleep apnea, joint stress, and cardiovascular risk factors. A BMI below 25 does not automatically exclude someone; physicians sometimes prescribe semaglutide for patients with lower BMI if metabolic dysfunction or family history suggests benefit. The goal is sustainable weight loss that improves overall health markers, not achievement of a specific number on a scale.

Medical History and Safety Considerations for Semaglutide Therapy

Certain medical conditions require careful evaluation before starting semaglutide injection. Patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 should not use GLP-1 medications. Additionally, those with severe gastrointestinal disease, uncontrolled type 2 diabetes requiring insulin, or active pancreatitis may need alternative approaches or physician supervision.

Medication interactions and concurrent health conditions must be reviewed with a healthcare provider before treatment begins. Patients taking other weight loss drugs, certain diabetes medications, or heart failure therapies should discuss combination safety with their doctor. PlexusDx works with licensed compounding pharmacies and encourages comprehensive health screening to ensure semaglutide injection aligns with your medication regimen and existing conditions.

Genetic Factors That Influence Semaglutide Response and Eligibility

Individual genetic variation affects how people respond to GLP-1 therapy, independent of BMI or age. Variants in the GLP1R gene (rs6923761), GIPR gene (rs1800437), and FTO gene (rs9939609) influence appetite signaling and metabolism, determining whether semaglutide delivers optimal weight loss or modest results. Some patients show stronger response with tirzepatide (a dual GIP/GLP-1 agonist), while others achieve excellent outcomes with semaglutide alone.

PlexusDx offers the Precision Peptide Genetic Test, a $99 add-on that maps 14 metabolic pathways and 49 peptide-related genes to predict your individual response pattern. This test is not a pharmacogenomic screening; instead, it reveals genetic predispositions in appetite regulation, insulin sensitivity, and energy expenditure. Knowing your genetic profile helps PlexusDx clinicians choose between semaglutide injection, tirzepatide, or combination therapies for maximum personalized efficacy.

Age, Pregnancy, and Special Population Considerations

Semaglutide is approved for adults 18 and older; younger teens may qualify for the pediatric formulation in specific cases under close supervision. Pregnant patients and those planning pregnancy should not start semaglutide, as pregnancy category data remains limited. Women of childbearing age using semaglutide are advised to use effective contraception and discontinue the medication at least 2 months before attempting conception.

Older adults and patients with chronic kidney disease, liver disease, or cardiovascular conditions qualify for semaglutide but require individualized dose titration and monitoring. PlexusDx serves all 50 states without insurance requirements, making treatment accessible to diverse populations. No membership fee or hidden costs apply—pricing starts at $149/month for compounded semaglutide injection, with HSA/FSA eligibility for many patients.

How PlexusDx Determines Your Personalized Eligibility

PlexusDx does not rely on BMI alone to determine semaglutide candidacy. During your initial consultation, providers review weight history, metabolic markers (fasting glucose, insulin, lipids), current medications, family history of diabetes or heart disease, and lifestyle factors. This comprehensive assessment identifies whether semaglutide injection, oral semaglutide, tirzepatide, or a dual-compound protocol best matches your health profile and goals.

After enrollment, patients can add the Precision Peptide Genetic Test to refine their treatment plan based on genetic predispositions in appetite and metabolism. PlexusDx compounds medications through licensed 503A pharmacies—never 503B—ensuring pharmaceutical-grade quality and safety. Your dose may need to go up as your body adjusts, but your price won't: flat monthly rates begin at $149 for compounded semaglutide injection across all commitment tiers.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I qualify for semaglutide if my BMI is below 30?

Yes. Patients with BMI 27–29.9 and weight-related health conditions (hypertension, type 2 diabetes, sleep apnea) often qualify. PlexusDx evaluates metabolic risk factors, not just BMI, to determine suitability for compounded semaglutide injection or other GLP-1 therapies.

What medical conditions disqualify someone from semaglutide?

Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 are absolute contraindications. Severe pancreatitis, active gastroparesis, and certain heart conditions may require physician review before starting semaglutide injection.

How does PlexusDx pricing work if my dose increases over time?

PlexusDx charges a flat monthly rate starting at $149/month for compounded semaglutide injection—your price remains the same regardless of dose escalation. Pricing is never structured as per-dose or dose-ladder; you pay one consistent monthly fee.

Will the Precision Peptide Genetic Test tell me if semaglutide will work for me?

The Precision Peptide Genetic Test ($99 add-on) maps genetic variants in GLP1R, GIPR, FTO, and MC4R genes to reveal your metabolic response pattern. Results help PlexusDx clinicians predict whether semaglutide or tirzepatide may deliver stronger results for your unique genetic profile.

Can I get semaglutide from PlexusDx without insurance?

Yes. PlexusDx serves all 50 states with no insurance requirement, no membership fee, and HSA/FSA eligibility. Compounded semaglutide injection from licensed 503A pharmacies starts at $149/month and is accessible to all qualified patients.

Who Qualifies for Semaglutide for Weight Loss?